Literature DB >> 30574947

Comment on: Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting.

Devesh Kumawat1, Pranita Sahay1, Dheepak Sundar1, Rohan Chawla1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30574947      PMCID: PMC6324095          DOI: 10.4103/ijo.IJO_1384_18

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


× No keyword cloud information.
Sir, We read with great interest the article titled “Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting” by Trujillo-Sanchez et al.[1] This is an interesting study highlighting that 27-Gauge vitrectomy surgeries can be performed as an office procedure under topical anesthesia without complications. However, there are few concerns that we would like to highlight. Although the safety of this procedure for cases with vitreous floaters has been proven by Wu et al., macular surgeries such as vitreomacular traction syndrome and epiretinal membrane require high precision during surgery and even flickering movements of the eye can result in undesirable complications.[2] Such cases represented only 9% of the total study group. Would the safety results represent a true picture for these cases? A significant percentage of patients (25%) had moderate-to-unbearable pain during surgery. The majority of patients reported pain during trocar insertion. The authors do not report on the type of entry for the trocar. 27-Gauge vitrectomy surgeries do not require a beveled sclerotomy entry.[3] If beveled entries were made, we would suggest that avoiding this step may help in further increasing the patient comfort. The authors report the mean surgical time to be 12.35 ± 8.21 min. They do not mention about induction of posterior vitreous detachment and peripheral shaving of vitreous. These crucial steps could not be completed within a few minutes. Limited core vitrectomy leaves behind a risk of detachment of residual vitreous later and development of new-onset floaters, retinal breaks, and even retinal detachments.[4] The follow-up of 30 days is too short to identify these complications and comment upon the safety of the procedure. We would suggest that the authors should recommend office-based vitrectomy under topical anesthesia only for cases requiring media clearing like vitreous floaters. Preoperative assessment of the macula should be possible to prevent intraoperative surprises. In addition, these cases should be under close observation for late onset retinal complications.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  4 in total

1.  A 27-gauge instrument system for transconjunctival sutureless microincision vitrectomy surgery.

Authors:  Yusuke Oshima; Taku Wakabayashi; Tatsuhiko Sato; Masahito Ohji; Yasuo Tano
Journal:  Ophthalmology       Date:  2009-10-31       Impact factor: 12.079

2.  Vitrectomy for floaters: prospective efficacy analyses and retrospective safety profile.

Authors:  Jerry Sebag; Kenneth M P Yee; Christianne A Wa; Laura C Huang; Alfredo A Sadun
Journal:  Retina       Date:  2014-06       Impact factor: 4.256

3.  A comparison between topical and retrobulbar anesthesia in 27-gauge vitrectomy for vitreous floaters: a randomized controlled trial.

Authors:  Rong Han Wu; Rui Zhang; Zhong Lin; Qi Hua Liang; Nived Moonasar
Journal:  BMC Ophthalmol       Date:  2018-07-07       Impact factor: 2.209

4.  Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting.

Authors:  Gloria Paulina Trujillo-Sanchez; Alejandro Gonzalez-De La Rosa; Jose Navarro-Partida; Luis Haro-Morlett; Juan Carlos Altamirano-Vallejo; Arturo Santos
Journal:  Indian J Ophthalmol       Date:  2018-08       Impact factor: 1.848

  4 in total
  1 in total

1.  Response to comment on: Feasibility and safety of vitrectomy under topical anesthesia in an office-based setting.

Authors:  Gloria P Trujillo-Sanchez; Alejandro Gonzalez-De la Rosa; Jose Navarro-Partida; Luis Haro-Morlett; Juan C Altamirano-Vallejo; Arturo Santos
Journal:  Indian J Ophthalmol       Date:  2019-01       Impact factor: 1.848

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.